Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

506
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
506
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

KetoFLEX 12/3 Diet and Cognitive Health: A Precision-Nutrition Perspective on Mechanisms, Emerging Evidence, and Future Directions.

Nutrients·2026
Same author

Almost a coin flip: Chance-like performance on TOMM Trial 1 using a sham extrasensory perception condition.

Applied neuropsychology. Adult·2026
Same author

Construct Validation of a Remote Brain Health Assessment Battery to Evaluate Vocational Aptitude and Factors Associated With Cognitive Resilience in the Military: Observational Trial.

JMIR formative research·2026
Same author

A cross-cultural incremental effects meta-analysis of acceptance and commitment therapy for depression: does targeting depression even matter?

Cognitive behaviour therapy·2026
Same author

Linking Cognitive Variability and Alzheimers Disease Biomarkers by Neurocognitive Status.

medRxiv : the preprint server for health sciences·2026
Same author

Drinking patterns, drinking-at-risk, and the influence of the COVID-19 pandemic in eight European countries.

Alcohol and alcoholism (Oxford, Oxfordshire)·2026

Related Experiment Video

Updated: Jul 14, 2025

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.2K

Precision Medicine Approach to Alzheimer's Disease: Rationale and Implications.

Dale E Bredesen1, Kat Toups2, Ann Hathaway3

  • 1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.

Journal of Alzheimer'S Disease : JAD
|October 9, 2023
PubMed
Summary

Precision medicine offers a promising new approach to Alzheimer's disease (AD) by treating it as chronic innate encephalitis. This strategy targets multiple contributors to cognitive decline, unlike traditional single-treatment trials.

Keywords:
Alzheimer’s diseaseMRI volumetricsclinical trialmild cognitive impairmentneurodegenerationsystems

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.6K
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.1K

Related Experiment Videos

Last Updated: Jul 14, 2025

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.2K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.6K
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.1K

Area of Science:

  • Neurodegenerative disease research
  • Precision medicine in neurology
  • Alzheimer's disease pathophysiology

Background:

  • Limited success in neurodegenerative disease therapeutics.
  • Current models may not accurately predict disease or identify optimal targets.
  • Standard clinical trials often use a single treatment modality, potentially missing key disease drivers.

Purpose of the Study:

  • Review the rationale for precision medicine in Alzheimer's disease (AD) prevention and treatment.
  • Present results and implications from recent proof-of-concept clinical trials.
  • Discuss the potential of a novel AD model as chronic innate encephalitis.

Main Methods:

  • Review of existing literature and recent proof-of-concept clinical trial data.
  • Analysis of a precision medicine approach versus traditional monotherapeutic strategies.
  • Discussion of challenges and requirements for implementing precision medicine in AD care.

Main Results:

  • Precision medicine, targeting multiple contributors to cognitive decline, shows promise for AD.
  • Recent trials suggest AD may be a chronic innate encephalitis causing network insufficiency.
  • This approach offers potential for enhanced outcomes when combined with pharmaceutical treatments.

Conclusions:

  • Precision medicine, based on a novel AD pathophysiology model, offers hope beyond current monotherapeutic approaches.
  • Large-scale randomized controlled trials are needed to establish precision medicine as a standard of care.
  • Implementing precision medicine requires significant changes in clinical trial design, healthcare infrastructure, and reimbursement.